Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOPE: Dapagliflozin for Coronary Atherosclerosis Progression in Type 2 Diabetes
NCT07614230Phase 4Recruiting
- Sponsor
- Junjie Yang
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in Coronary atherosclerosis (CAD), type 2 diabetes mellitus (T2DM), sponsored by Junjie Yang. Started Jan 2026; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Coronary atherosclerosis (CAD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07614230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614230.